IC50 values of BTKi’s for inhibition of platelet aggregation induced by CD32 cross-linking and anti-CD9 antibody in blood
| . | IC50, µM . | |
|---|---|---|
| CD32 cross-linking (n = 6) . | Anti-CD9 antibody (n = 5) . | |
| Ibrutinib | 0.08 ± 0.04 | 0.05 ± 0.01 |
| Zanubrutinib | 0.11 ± 0.03 | 0.09 ± 0.02 |
| Acalabrutinib | 0.38 ± 0.16 | 0.26 ± 0.08 |
| Tirabrutinib | 0.42 ± 0.16 | 0.26 ± 0.06 |
| Evobrutinib | 1.13 ± 0.48 | 0.92 ± 0.15 |
| Fenebrutinib | 0.011 ± 0.0039 | — |
| . | IC50, µM . | |
|---|---|---|
| CD32 cross-linking (n = 6) . | Anti-CD9 antibody (n = 5) . | |
| Ibrutinib | 0.08 ± 0.04 | 0.05 ± 0.01 |
| Zanubrutinib | 0.11 ± 0.03 | 0.09 ± 0.02 |
| Acalabrutinib | 0.38 ± 0.16 | 0.26 ± 0.08 |
| Tirabrutinib | 0.42 ± 0.16 | 0.26 ± 0.06 |
| Evobrutinib | 1.13 ± 0.48 | 0.92 ± 0.15 |
| Fenebrutinib | 0.011 ± 0.0039 | — |
Values are mean ± SD. BTKi’s were preincubated for 60 minutes (or 15 minutes for fenebrutinib) before Fc receptor stimulation.